Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 1,032 shares of common stock on 09/11/2025 at $26.83 per share, reducing his direct holdings to 184,186 shares. The Form 4, signed 09/15/2025, states the sale was made under a Rule 10b5-1 trading plan established 03/08/2024 to cover tax withholding obligations tied to vesting restricted stock. No derivative transactions are reported.
Todd Berard, Chief Marketing Officer of BioLife Solutions, reported a sale of company stock on 09/11/2025. The Form 4 shows he disposed of 358 shares of common stock at a price of $26.83 per share under a Rule 10b5-1 trading plan adopted 03/08/2024 to satisfy tax withholding obligations tied to the vesting of restricted stock. After the transaction, Mr. Berard beneficially owned 133,906 shares directly. The filing is signed and dated 09/15/2025.
Sean Werner, Chief Technology Officer of BioLife Solutions, reported a sale of 72 shares of common stock on 09/11/2025 at $26.83 per share. After the sale he beneficially owns 26,312 shares (direct). The filing states the sale was executed under a Rule 10b5-1 trading plan adopted effective 09/01/2021 to satisfy tax withholding obligations tied to the vesting of restricted stock. The Form 4 is signed 09/15/2025.
BIOLIFE SOLUTIONS, INC. (BLFS) Rule 144 notice reports proposed sale of 714 common shares by a holder through Morgan Stanley Smith Barney on 09/15/2025 on NASDAQ, with an aggregate market value listed as $18,214.14 and total shares outstanding shown as 47,905,265. The securities were acquired as restricted stock units on 09/08/2025 from the issuer and the filing records payment or settlement on that same date.
The filer disclosed three prior sales by the same person in the past three months: 711 shares via a 10b5-1 sale on 06/16/2025 for $15,805.53, 198 shares on 07/07/2025 for $4,409.46, and 219 shares on 08/26/2025 for $5,571.36. The filing includes a representation that the seller is not aware of undisclosed material adverse information and notes the option to rely on a 10b5-1 plan; no plan adoption date or signature block details are present in the provided content.
Insider sale under pre-existing plan: Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, reported a sale of 531 shares of BioLife common stock on 08/26/2025 at a price of $25.44 per share. The sale was made pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported sale, the filing shows Mr. Mathew beneficially owns 352,051 shares directly. The Form 4 was signed on 08/28/2025 and the filer indicated the transaction was executed under the 10b5-1 plan.
Karen A. Foster, Chief Quality and Operations of BioLife Solutions Inc. (BLFS), reported a sale of 413 shares of the company's common stock on 08/26/2025 at a price of $25.44 per share. Following the transaction, Ms. Foster beneficially owns 194,183 shares, held directly.
The filing states the sale was executed under a Rule 10b5-1(c) trading plan adopted by the reporting person on 02/24/2022 to satisfy tax withholding obligations related to the vesting of restricted stock. The Form 4 is signed and dated 08/28/2025.
Sean Werner, Chief Technology Officer of BioLife Solutions, sold 111 shares of the company's common stock on 08/26/2025 at $25.44 per share under a pre-existing Rule 10b5-1(c) trading plan. The Form 4 shows the sale was to satisfy tax withholding obligations tied to the vesting of restricted stock and the reporting person retained 26,384 shares of common stock after the transaction. The filing is signed by Sean Werner on 08/28/2025 and indicates the Form is filed by one reporting person.
Insider sale under 10b5-1 plan: Troy Wichterman, Chief Financial Officer of BioLife Solutions, sold 590 shares of BioLife Solutions Inc. (BLFS) on 08/26/2025 at a price of $25.44 per share. After the sale, Mr. Wichterman beneficially owned 185,218 shares, held directly. The filing states the sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on 02/24/2022 to satisfy tax withholding obligations arising from the vesting of restricted stock. The Form 4 is signed by the reporting person on 08/28/2025.
Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 219 shares of common stock on 08/26/2025 at $25.44 per share under a pre-established Rule 10b5-1(c) plan. The filing states the sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock. After the reported transaction, the reporting person beneficially owned 78,304 shares of BioLife Solutions common stock, held directly.
The sale was made pursuant to a 10b5-1 trading plan adopted 02/24/2022, which the filer checked on the form to indicate pre-planned execution; the Form 4 is signed and dated 08/28/2025.
Insider sale under a pre-established plan: Todd Berard, Chief Marketing Officer of BioLife Solutions Inc. (BLFS), reported the sale of 354 shares of common stock on 08/26/2025 at a price of $25.44 per share. After the transaction, Berard beneficially owned 134,264 shares, held directly. The filing states the sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 02/24/2022 to satisfy tax withholding obligations from restricted stock vesting. The Form 4 is a routine disclosure of a planned sale; no new grants, options, or derivative transactions are reported.